Annexon, Inc.
NASDAQ:ANNX · NASDAQ Global Select
-$0.04 today
Vol 5.43M · Avg 2.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-97.7%
avg -47.5%
ROIC
-91.0%
avg -93.9%
ROA
-74.5%
avg -69.3%
Analysis
ROA is currently the strongest return metric at -74.5% versus its period average of -69.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Douglas Love | Chief Executive Officer, President & Director | $1.06M | — | 58 | $1.25M | 1.05% |
Dean R. Artis | Chief Scientific Officer & Executive Vice President | $797,380.00 | — | 65 | $180,093.00 | 0.15% |
Ted Yednock | Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board | $737,794.00 | — | 68 | $0.00 | <0.01% |
Jamie Dananberg | Executive Vice President & Chief Medical Officer | $715,233.00 | — | 68 | $123,582.00 | 0.10% |
Jennifer Lew | Executive Vice President, Chief Financial Officer & Corporate Secretary | $700,017.00 | — | 53 | $170,700.00 | 0.14% |
Michael Overdorf | Executive Vice President & Chief Business Officer | $580,469.00 | — | 55 | $182,625.00 | 0.15% |
Shikhar Agarwal | Senior Vice President & Head of Commercial | — | — | — | — | — |
Lloyd Clark | Senior Vice President of Ophthalmology Strategy & Innovation | — | — | — | — | — |
Sunil Mehta | Senior Vice President of Medical Affairs | — | — | — | — | — |
Henk-Andre Kroon | Senior Vice President of Translational Medicine | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$12.35M
Sells
13
$321,415.27
Net Sentiment
+$12.03M
Net buying
Most Active
Carson William H.
10 transactions
1–10 of 30
Analysis
Insiders reported 17 buys worth $12.35M and 13 sells worth $321,415.27 over the last 12 months. That adds up to net buying of $12.03M. Carson William H. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$851.41M
Aura Biosciences, Inc.
NASDAQ:AURA
$401.57M
DBV Technologies S.A.
NASDAQ:DBVT
$382.75M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$306.06M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$302.52M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
Altimmune, Inc.
NASDAQ:ALT
$239.97M
Korro Bio, Inc.
NASDAQ:KRRO
$125.76M
enGene Holdings Inc.
NASDAQ:ENGN
$88.06M
Who manages ANNX?
Annexon, Inc. (ANNX) lists 10 active executives. The top listed executive is Jennifer Lew, Executive Vice President, Chief Financial Officer & Corporate Secretary.
Are ANNX insiders buying or selling?
Recent insider activity shows net buying of $63.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.